Home › NDC Lookup › RxCUI directory › RxCUI 197741

Guaifenesin 200 MG Oral Tablet — RxCUI 197741

RxNorm drug concept · Semantic clinical drug
RxCUI 197741 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197741
Official nameGuaifenesin 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped7
Package NDCs mapped7
Reported Medicaid activity (SDUD)12,166 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Guaifenesin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Guaifenesin is what's called an expectorant — it works to thin and loosen the mucus sitting in your chest and airways. That makes it easier to cough the mucus up and out, so instea...
  • What exactly does guaifenesin do for my cough?
  • Guaifenesin is meant for short-term use. If your cough isn't getting better after 7 days, keeps coming back, or shows up alongside a fever, rash, or a headache that won't go away,...
  • How long can I take it before I should call my doctor?
📖 Read our full Guaifenesin guide →

🕸️ Concept Web — How Guaifenesin 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Guaifenesin 200 MG Oral Tablet RxCUI 197741

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Guaifenesin 5032
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Guaifenesin Oral Tablet 372360
    • Guaifenesin Oral Product 1159704
    • Guaifenesin Pill 1159705
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Guaifenesin 200 MG 317384

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Guaifenesin 200 MG SCDC · 317384
  • Guaifenesin Oral Tablet SCDF · 372360
  • Guaifenesin Oral Product SCDG · 1159704
  • Guaifenesin Pill SCDG · 1159705

📦 FDA Products & Package NDCs

7 products · 7 package NDCs
7 package NDCs map to RxCUI 197741 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00904-5154-60 100 TABLET in 1 BOTTLE, PLASTIC (0904-5154-60) Guaifenesin Major Pharmaceuticals 2009-10-05
10135-0789-01 100 TABLET in 1 BOTTLE (10135-789-01) Guaifenesin 200mg Marlex Pharmaceuticals Inc 2024-03-01
53499-0232-01 100 TABLET in 1 BOTTLE (53499-0232-1) Air Power Schwabe North America, Inc 2021-06-14
54738-0980-01 100 TABLET in 1 BOTTLE (54738-980-01) Mucus Relief Richmond Pharmaceuticals, Inc. 2016-03-01
69517-0148-03 300 TABLET in 1 BOTTLE (69517-148-03) Guaifenesin 200mg HEALTHLIFE OF USA LLC 2025-08-22
71610-0098-18 3000 TABLET in 1 BOTTLE (71610-098-18) Mucus Relief Aphena Pharma Solutions - Tennessee, LLC 2018-07-16
71610-0434-18 3000 TABLET in 1 BOTTLE (71610-434-18) Guaifenesin 200mg Aphena Pharma Solutions - Tennessee, LLC 2020-06-16
Observed labelers: Aphena Pharma Solutions - Tennessee, LLC (2) · HEALTHLIFE OF USA LLC (1) · Major Pharmaceuticals (1) · Marlex Pharmaceuticals Inc (1) · Richmond Pharmaceuticals, Inc. (1) · Schwabe North America, Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.0318
Range $0.0318–$0.0318 · middle 50% $0.0318–$0.0318 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.